Research article · 15 Apr 2026
Conference abstractPublished 20 Aug 2012
Muscle wasting in chronic kidney disease: Mechanisms and therapeutic strategies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
M uscle wasting is triggered by complications of chronic kidney disease (CKD) including metabolic acidosis, insulin resistance, glucocorticoids, angiotensin II and inflammation (e.g., IL-6). These conditions activate caspase-3 and the ubiquitin proteasome system (UPS) to stimulate the degradation of protein; protein synthesis may also be reduced. Unfortunately, there are no approved, regularly effective treatments for the muscle wasting that occurs frequently in patients with CKD. We have found that CKD-stimulate myostatin expression in muscle. Myostatin is a negative regulator for muscle growth. Inhibition myostatin using humanized peptibody, we found the increased body and muscle weight in mice even with CKD. Inhibition of myostatin improved IGF1/insulin signaling pathway in muscle, increases satellite cell activation. It also inhibited CDK-stimulated pro- inflammatory cytokine production including IL-6. In CKD patients, morbidity and mortality correlate with circulating IL-6 levels. In rodent, IL-6 injection causes wasting and IL-6 inhibition partially ameliorates it. Since IL-6 activates Signal transducer and activator of transcription 3 (STAT3), we examined this molecule in muscle of CKD mice. In skeletal muscle of mice with CKD, we find increased p-STAT3 and expression of its target genes, including SOCS3 and C/EBP δ . C/EBP δ then stimulates expression of myostatin. Experimentally, we find that constitutively activated STAT3 is sufficient to cause myofiber protein wasting and when we inhibited STAT3 with a small molecule STAT3 inhibitor, there was suppression of IL-6-induced myotubes wasting as well as CKD-induced muscle atrophy in mice. Taken together, our results strongly implicate STAT3 as a causative trigger of CKD- induced muscle wasting. The STAT3 inhibitor is useful not only for uncovering cell signaling that causes muscle proteolysis but also could become a therapeutic strategy to reverse the muscle atrophy induced by CKD and potentially other conditions
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Liping Zhang”
